Psychosocial state after bariatric surgery is associated with the serotonin-transporter promoter polymorphism

Defrancesco, Michaela; Liebaert, Jessica; Kemmler, Georg; Aigner, Franz; Niederstätter, Harald; Parson, Walther; Kinzl, Johann F.

doi:10.1007/s40519-013-0045-8

Cited by 9 publications

(13 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, in the current population, data from SLC6A4 promoter showed that this genetic variant was not independently associated with total weight loss, although it had a weak impact on the duration of the maintenance program. These results are in agreement with those obtained by Defrancesco et al [55], who found no influence of this genotype on weight loss, current weight, or weight before surgery in a severe obese population although the psychosocial state after bariatric surgery was associated with serotonin-transporter promoter polymorphism.…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

Serotonin‐transporter promoter polymorphism modulates the ability to control food intake: Effect on total weight loss

Bonnet

Gómez-Abellán

Vera

et al. 2017

Molecular Nutrition Food Res

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

“…These results are in agreement with those obtained by Defrancesco et al. , who found no influence of this genotype on weight loss, current weight, or weight before surgery in a severe obese population although the psychosocial state after bariatric surgery was associated with serotonin‐transporter promoter polymorphism.…”

Section: Discussionsupporting

confidence: 92%

Serotonin‐transporter promoter polymorphism modulates the ability to control food intake: Effect on total weight loss

Bonnet

Gómez-Abellán

Vera

et al. 2017

Molecular Nutrition Food Res

View full text Add to dashboard Cite

show abstract

“…For example, bariatric surgery (Roux-en-Y gastric bypass [RYGB]) has been shown to significantly affect serotonin metabolism in both animals (51,55) and humans (56). Moreover, RYGB is regarded as a last resort but very successful treatment for morbidly obese patients, because next to inducing weight loss up to 50% of the original weight, it also decreases the risk of T2DM and cardiovascular pathology (57,58).…”

Section: Innovative Strategies For Novel Therapeutics In T2dmmentioning

confidence: 99%

Insights Into the Role of the Microbiome in Obesity and Type 2 Diabetes

et al. 2014

View full text Add to dashboard Cite

The worldwide prevalence of obesity and type 2 diabetes mellitus (T2DM) continues to rise at an alarming pace. Recently the potential role of the gut microbiome in these metabolic disorders has been identified. Obesity is associated with changes in the composition of the intestinal microbiota, and the obese microbiome seems to be more efficient in harvesting energy from the diet. Lean male donor fecal microbiota transplantation (FMT) in males with metabolic syndrome resulted in a significant improvement in insulin sensitivity in conjunction with an increased intestinal microbial diversity, including a distinct increase in butyrate-producing bacterial strains. Such differences in gut microbiota composition might function as early diagnostic markers for the development of T2DM in high-risk patients. Products of intestinal microbes such as butyrate may induce beneficial metabolic effects through enhancement of mitochondrial activity, prevention of metabolic endotoxemia, and activation of intestinal gluconeogenesis via different routes of gene expression and hormone regulation. Future research should focus on whether bacterial products (like butyrate) have the same effects as the intestinal bacteria that produce it, in order to ultimately pave the way for more successful interventions for obesity and T2DM. The rapid development of the currently available techniques, including use of fecal transplantations, has already shown promising results, so there is hope for novel therapies based on the microbiota in the future.

show abstract

“…The difference in gut microbiota composition between obese and lean mice and humans is accompanied by variations in plasma metabolite profile [ 24 , 25 ], including serotonin [ 26 , 27 ]. Likewise, weight loss induced by RYGB significantly increased central SERT in both animals and humans [ [28] , [29] , [30] ] and striatal dopamine D 2/3 receptor availability in humans [ 31 ]. It has recently become apparent that intestinal bacteria can regulate host serotonin metabolism [ [32] , [33] , [34] ], especially via the kynurenine pathway [ [35] , [36] , [37] ].…”

Section: Introductionmentioning

confidence: 99%

Infusion of donor feces affects the gut–brain axis in humans with metabolic syndrome

Hartstra

Schüppel

Imangaliyev

et al. 2020

Molecular Metabolism

View full text Add to dashboard Cite

Objective Increasing evidence indicates that intestinal microbiota play a role in diverse metabolic processes via intestinal butyrate production. Human bariatric surgery data suggest that the gut-brain axis is also involved in this process, but the underlying mechanisms remain unknown. Methods We compared the effect of fecal microbiota transfer (FMT) from post-Roux-en-Y gastric bypass (RYGB) donors vs oral butyrate supplementation on ( 123 I-FP-CIT-determined) brain dopamine transporter (DAT) and serotonin transporter (SERT) binding as well as stable isotope-determined insulin sensitivity at baseline and after 4 weeks in 24 male and female treatment-naïve metabolic syndrome subjects. Plasma metabolites and fecal microbiota were also determined at these time points. Results We observed an increase in brain DAT after donor FMT compared to oral butyrate that reduced this binding. However, no effect on body weight and insulin sensitivity was demonstrated after post-RYGB donor feces transfer in humans with metabolic syndrome. Increases in fecal levels of Bacteroides uniformis were significantly associated with an increase in DAT, whereas increases in Prevotella spp. showed an inverse association. Changes in the plasma metabolites glycine, betaine, methionine, and lysine (associated with the S -adenosylmethionine cycle) were also associated with altered striatal DAT expression. Conclusions Although more and larger studies are needed, our data suggest a potential gut microbiota-driven modulation of brain dopamine and serotonin transporters in human subjects with obese metabolic syndrome. These data also suggest the presence of a gut-brain axis in humans that can be modulated. NTR registration 4488.

show abstract

Psychosocial state after bariatric surgery is associated with the serotonin-transporter promoter polymorphism

Abstract: Quality of life, mood, and resilience but not weight loss after bariatric surgery are negatively influenced by the s-allele of the 5-HTTLPR polymorphism.

Cited by 9 publications

References 34 publications

Serotonin‐transporter promoter polymorphism modulates the ability to control food intake: Effect on total weight loss

Serotonin‐transporter promoter polymorphism modulates the ability to control food intake: Effect on total weight loss

Insights Into the Role of the Microbiome in Obesity and Type 2 Diabetes

Infusion of donor feces affects the gut–brain axis in humans with metabolic syndrome

Contact Info

Product

Resources

About